MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

O I P Substitute for form 1449B/PTO			Complete if Known		
INFORMATIO	ON DISCLO	SURE	Application Number	09/147,443	
STATEMENT BY APPLICANT			Filing Date	01/21/1999	
			First Named Inventor	Andreas Morell	
\2 \mathred{\2}			Group Art Unit	1644	
(use as many sheets as necessary)			Examiner Name	Francois P. Vandervegt	
Sheet TRADEM	of	2	Attorney Docket Number	029860-0114	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				
R	A1	BARBAS III et al., "Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen-Specific Fabs," <u>Methods: A Comparison to Methods in Enzymology</u> , April 1991, pp. 119-124, Vol. 2, No. 2, Academic Press, Inc.	and the second			
	A2	CHÉRIF-ZAHAR et al., "Molecular cloning and protein structure of a human blood group Rh polypeptide," Proc. Natl. Acad. Sci. USA, August 1990, pp. 6243-6247, Vol. 87				
	А3	CRAWFORD et al., "Production of Human Monoclonal Antibody to Rhesus D Antigen," <u>The Lancet,</u> February 19, 1983, pp. 386-388, Vol. I, No. 8321				
	A4	DZIEGIEL et al., "Recombinant Antibody Against the Erythrocyte Antigen, Rhesus D," Abstract No. T513, Journal of Cellular Biochemistry, February 26-April 17, 1994, p. 212, Supplement 18D, Wiley-Liss				
	A5	HUGHES-JONES, "Human Monoclonal Antibodies and Haemolytic Disease of the Newborn," <u>British</u> <u>Journal of Haematology</u> , November 1988, pp. 263-265, Vol. 70, No. 3, Blackwell Scientific Publications				
	A6	ISSITT, "Genetics of the Rh blood group system: some current concepts," Medical Laboratory Sciences, 1988, pp. 395-404, Vol. 45, Blackwell Scientific Publications				
	Α7	KOZBOR et al., "The production of monoclonal antibodies from human lymphocytes," <u>Immnology Today</u> , 1983, pp. 72-79, 1983, Vol. 4, No. 3, Elsevier Science Publishers B.V.				
	A8	LE VAN KIM et al., "Molecular cloning and primary structure of the human blood group RhD polypeptide," Proc. Natl. Acad. Sci. USA, November 1992, pp. 10925-10929, Vol. 89				
	A9	MOURO et al., "Rearrangements of the Blood Group RhD Gene Associated with the D ^{VI} Category Phenotype," <u>Blood</u> , February 15, 1994, pp. 1129-1135, Vol. 83, No. 4, The American Society of Hematology				
	A10	PARADIS et al., "Protective Effect of the Membrane Skeleton on the Immunologic Reactivity of the Human Red Cell Rh₀(D) Antigen," <u>The Journal of Immunology</u> , July 1, 1986, pp. 240-244, Vol. 137, No. 1, The American Association of Immunologies				
	A11	PERSSON et al., "Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning," Proc. Natl. Acad. Sci. USA, March 1991, pp. 2432-2436, Vol. 88				
	A12	RACE et al. (Eds.), Blood Groups in Man, 1975, TABLE OF CONTENTS ONLY, Blackwell Scientific Publications				

Examiner Signature	80.1	Intels-	Date Considered	7/30/04
4573444 8841575	4 111 4 11			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

1	Substitut	e for form 1449B	/PTO	Complete if Known			
A	WFORMA	TION DISCLO	SURE	Application Number	09/147,443		
/	ŠŤÀTEMI	ENT BY APPLI	CANT	Filing Date	01/21/1999		
ı	MAY 0 6 2004 (US) es many sheets as necessary)			First Named Inventor	Andreas Morell		
v				Group Art Unit	1644		
\3				Examiner Name	Francois P. Vandervegt		
1	StrangineMART 2	of	2	Attorney Docket Number	029860-0114		

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
W	A13	SELINGER, "Immunoprophylaxis for rhesus disease – expensive but worth it?" <u>British Journal of Obstetrics</u> and Gynaecology, June 1991, pp. 509-512, Vol. 98, No. 6, Blackwell Scientific Publications					
	A14	SIEGEL et al., "Isolation of Human Anti-Red Blood Cell Antibodies by Repertoire Cloning," <u>Annals New York Academy of Sciences</u> , September 29, 1995, pp. 547-558, Vol. 764, New York Academy of Sciences, USA					
	A15	TIPPETT et al., "The Rh Antigen D: Partial D Antigens and Associated Low Incidence Antigens," <u>Vox Sanguinis</u> , February 1996, pp. 123-131, Vol. 70, S. Karger AG, Basel					
	A16	VOGEL et al., "Human anti-IgE antibodies by repertoire cloning," <u>Eur. J. Immunol.</u> , May 1994, pp. 1200- 1207, Vol. 24, VCH Verlagsgesellschaft mbH, Weinheim					
	A17	WILLIAMSON et al., "Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries," <u>Proc. Natl. Acad. Sci. USA</u> , May 1993, pp. 4141-4145, Vol. 90					
(A18	ZEBEDEE et al., "Human combinatorial antibody libraries to hepatitis B surface antigen," <u>Proc. Natl. Acad. Sci. USA</u> , April 1992, pp. 3175-3179, Vol. 89					
			_				
			-				
	-		_				

			-		
Examiner Signature	12. P-	- Inh li	Date Considered	7/30/04	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether ownot citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.